Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

STRN (Striatin)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

STRN-ALK fusion + MET amplification	Non Small Cell Lung Cancer	STRN-ALK fusion + MET amplification	Non Small Cell Lung Cancer	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3
STRN-ALK fusion + MET amplification	Non Small Cell Lung Cancer	STRN-ALK fusion + MET amplification	Non Small Cell Lung Cancer	crizotinib + ensartinib Sensitive: C3 – Early Trials crizotinib + ensartinib Sensitive : C3	crizotinib + ensartinib Sensitive: C3 – Early Trials crizotinib + ensartinib Sensitive : C3
STRN-ALK fusion	Lung Adenocarcinoma	STRN-ALK fusion	Lung Adenocarcinoma	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4
STRN-ALK fusion	Non Small Cell Lung Cancer	STRN-ALK fusion	Non Small Cell Lung Cancer	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
STRN-NTRK2 fusion + CDKN2B Deletion	Soft Tissue Sarcoma	STRN-NTRK2 fusion + CDKN2B Deletion	Soft Tissue Sarcoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
EGFR exon 19 deletion + STRN-ALK fusion	Non Small Cell Lung Cancer	EGFR exon 19 deletion + STRN-ALK fusion	Non Small Cell Lung Cancer	crizotinib + gefitinib Sensitive: C4 – Case Studies crizotinib + gefitinib Sensitive : C4	crizotinib + gefitinib Sensitive: C4 – Case Studies crizotinib + gefitinib Sensitive : C4
STRN-ALK fusion + KRAS G13D	Colorectal Cancer	STRN-ALK fusion + KRAS G13D	Colorectal Cancer	ceritinib Resistant: C4 – Case Studies ceritinib Resistant : C4	ceritinib Resistant: C4 – Case Studies ceritinib Resistant : C4
STRN-ALK rearrangement	Mesothelioma	STRN-ALK rearrangement	Mesothelioma	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
STRN-ALK fusion	Non Small Cell Lung Cancer	STRN-ALK fusion	Non Small Cell Lung Cancer	alectinib Resistant: C4 – Case Studies alectinib Resistant : C4	alectinib Resistant: C4 – Case Studies alectinib Resistant : C4
STRN-ALK fusion + EML4-ALK fusion + EGFR T790M	Lung Adenocarcinoma	STRN-ALK fusion + EML4-ALK fusion + EGFR T790M	Lung Adenocarcinoma	crizotinib + osimertinib Sensitive: C4 – Case Studies crizotinib + osimertinib Sensitive : C4	crizotinib + osimertinib Sensitive: C4 – Case Studies crizotinib + osimertinib Sensitive : C4
STRN exon 2-ALK exon 20 fusion	Mesothelioma	STRN exon 2-ALK exon 20 fusion	Mesothelioma	cisplatin + pemetrexed Resistant: C4 – Case Studies cisplatin + pemetrexed Resistant : C4	cisplatin + pemetrexed Resistant: C4 – Case Studies cisplatin + pemetrexed Resistant : C4
EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification	Non Small Cell Lung Cancer	EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification	Non Small Cell Lung Cancer	osimertinib Resistant: C4 – Case Studies osimertinib Resistant : C4	osimertinib Resistant: C4 – Case Studies osimertinib Resistant : C4